Literature DB >> 9024962

Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms.

L L von Moltke1, S X Duan, D J Greenblatt, S M Fogelman, J Schmider, J S Harmatz, R I Shader.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9024962     DOI： 10.1016/s0006-3223(96)00406-4

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  6 in total

Review 1.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

2.  Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction.

Authors:  Yijin Liu; Michael Jann; Chad Vandenberg; Chin B Eap; Shahab A Shamsi
Journal:  J Chromatogr A       Date:  2015-10-03       Impact factor: 4.759

Review 3.  Venlafaxine extended-release: a review of its use in the management of major depression.

Authors:  K Wellington; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 4.  Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.

Authors:  Siamak Cyrus Khojasteh; Saileta Prabhu; Jane R Kenny; Jason S Halladay; Anthony Y H Lu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-02-19       Impact factor: 2.441

5.  Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.

Authors:  Michael W Jann; Vicky Spratlin; Kathryn Momary; Hailing Zhang; David Turner; Scott R Penzak; Alan Wright; Chad VanDenBerg
Journal:  Eur J Clin Pharmacol       Date:  2011-12-16       Impact factor: 2.953

Review 6.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.